Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 586 AL 600

Plasma Aβ biomarker for early diagnosis and prognosis of Alzheimer's disease - a systematic review

Ebbesen SU, Høgh P, Zibrandtsen I.

Dan Med J. 2023 May 10;70(6):A07220446.

Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives

Lista S, González-Domínguez R, López-Ortiz S, González-Domínguez Á, Menéndez H, Martín-Hernández J, Lucia A, Emanuele E, Centonze D, Imbimbo BP, Triaca V, Lionetto L, Simmaco M, Cuperlovic-Culf M, Mill J, Li L, Mapstone M, Santos-Lozano A, Nisticò R.

Ageing Res Rev. 2023 Aug;89:101987. doi: 10.1016/j.arr.2023.101987. Epub 2023 Jun 19.

Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo

Therriault J, Gauthier S, Rosa-Neto P.

J Prev Alzheimers Dis. 2023;10(3):381-386. doi: 10.14283/jpad.2023.52.

White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework

Ng KP, Shen JY, Chiew HJ, Ng ASL, Kandiah N, Rosa-Neto P, Gauthier S.

J Prev Alzheimers Dis. 2023;10(3):387-400. doi: 10.14283/jpad.2023.53.

Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias

Hu WT, Nayyar A, Kaluzova M.

Neurotherapeutics. 2023 Jul;20(4):955-974. doi: 10.1007/s13311-023-01370-8. Epub 2023 Jun 28.

Predicting cognitive decline in older people by structural and molecular imaging

Teipel S, Tang Y, Boccardi M.

Curr Opin Neurol. 2023 Aug 1;36(4):253-263. doi: 10.1097/WCO.0000000000001172. Epub 2023 Jun 19.

MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease

Filippi M, Cecchetti G, Agosta F.

Curr Opin Neurol. 2023 Aug 1;36(4):239-244. doi: 10.1097/WCO.0000000000001177. Epub 2023 Jun 23.

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers

Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D.

Curr Opin Neurol. 2023 Aug 1;36(4):264-275. doi: 10.1097/WCO.0000000000001173. Epub 2023 Jun 9.

Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers

Kimura T, Sato H, Kano M, Tatsumi L, Tomita T.

FEBS Open Bio. 2024 Feb;14(2):181-193. doi: 10.1002/2211-5463.13667. Epub 2023 Jul 8.

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis

Jeremic D, Navarro-López JD, Jiménez-Díaz L.

Ageing Res Rev. 2023 Sep;90:102012. doi: 10.1016/j.arr.2023.102012. Epub 2023 Jul 7.

The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development

Singh R, Hussain J, Kaur A, Jamdare BG, Pathak D, Garg K, Kaur R, Shankar S, Sunkaria A.

Ageing Res Rev. 2023 Sep;90:102002. doi: 10.1016/j.arr.2023.102002. Epub 2023 Jul 7.

The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment

Ghareghani M, Rivest S.

Int J Mol Sci. 2023 Jun 30;24(13):10905. doi: 10.3390/ijms241310905.

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials

Rahman-Filipiak A, Bolton C, Grill JD, Rostamzadeh A, Chin N, Heidebrink J, Getz S, Fowler NR, Rosen A, Lingler J, Wijsman E, Clark L; Advisory Group on Risk Evidence Education in Dementia (AGREED).

Alzheimers Dement. 2023 Sep;19(9):4270-4275. doi: 10.1002/alz.13380. Epub 2023 Jul 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias